Objective <p>Our study examines the consistency and transferability of cost-effectiveness values, specifically the incremental cost-effectiveness ratio (ICER), focusing on several disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) approved by four of the most established Health Technology Assessment (HTA) bodies.</p> Methods <p>Data of economic evaluation results for DMTs were extracted from the HTA reports published by four agencies. Descriptive statistics were employed to identify correlations between the accepted ICERs within and across agencies. Two different currency conversion approaches were employed to investigate the feasibility and efficiency for transferring accepted ICERs across jurisdictions.</p> Results <p>The study analysed ten DMTs that received positive recommendations from four agencies: the National Institute for Health and Care Excellence (NICE), Scottish Medicines Consortium (SMC), Pharmaceutical Benefits Advisory Committee (PBAC) and Canada’s Drug Agency (CDA). The consistency of accepted ICER values for the class of DMTs was observed within the four agencies; however, the commonality of accepted ICER values was only observed between some agencies, such as the CDA and NICE, as well as the PBAC and SMC. Purchasing power parity-adjusted ICER values were found to provide better transference of ICER outcomes as compared to the exchange-rate method.</p> Conclusion <p>This study highlighted the consistency of the economic evaluation for DMTs within the four agencies. We also identified a particularly strong alignment between NICE and the CDA, as well as the PBAC and SMC. Additionally, the examination of two ICER value conversion methods pinpointed key factors that could impact the transference of ICER values.</p>